Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Luci vs Youth & Soul

Luci
Graded #101

Higher grade

vs+9.399999999999999
Youth & Soul
Graded #294

Lower grade

The verdict

Luci takes it — 71/100 to 61.6/100.

Luci grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luci is a budget-focused GLP-1 telehealth platform offering compounded medications with upfront pricing: compounded semaglutide as low as $99/month and compounded tirzepatide as low as $145/month, plus oral…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLuci +10
84
74
Dose & formulationLuci +11
75
64
Clinical oversightLuci +17
71
54
Labs & monitoringYouth & Soul +7
53
60
FulfillmentLuci +15
70
55
Contract termsLuci +6
55
49
Luci · left barYouth & Soul · right bar

The numbers

MetricLuciYouth & Soul
WeighScore71/10061.6/100
GradeCC
Scorecard rank#101#294
Semaglutide$99/mo (starting dose, promotional rate, compounded)$149/mo (starting dose, compounded)
Tirzepatide$145/mo (starting dose, promotional rate, compounded)$399/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Luci

Graded #101 · C

Strengths

  • Budget-friendly compounded GLP-1 pricing (compounded semaglutide as low as $99/month, tirzepatide as low as $145/month)
  • Multiple formats: compounded semaglutide and tirzepatide injections plus oral semaglutide and tirzepatide pill kits
  • Upfront pricing with no insurance required and a fast 3-minute questionnaire to start
  • Care delivered through DrTelx, an independent US telehealth medical group, with ongoing support and dose optimization
  • HIPAA-compliant platform with a large self-reported member base (50,000+)

Where it loses points

  • Compounded medications are not FDA-approved for weight loss (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Available only in select U.S. states, and the full state list is not published
  • The compounding pharmacy partner is not named
  • Headline prices are 'as low as' rates (asterisked) — your actual monthly cost may be higher
  • No LegitScript certification displayed; marketing leans heavily on testimonials
Youth & Soul

Graded #294 · C

Strengths

  • Three GLP-1 tiers priced openly, with the dose range and every included component listed per tier
  • Full refund advertised if you are not approved
  • Physician consultation, prescription and shipping stated as included in the plan price
  • Ten treatment verticals under one account, from GLP-1 to HRT, peptides and mental health

Where it loses points

  • Describes its compounded medications as FDA-Approved Compounds, which is false: compounded drugs are not FDA-approved
  • Presents scraped third-party comments as testimonials, several using Reddit usernames and some describing brand Wegovy or Mounjaro
  • Its own copy promises never to fabricate testimonials while displaying those scraped comments
  • Homepage trust counters render as 0K+ medical professionals, 0.0M+ patients and 0M+ successful orders
  • Labels its compounded tirzepatide a Mounjaro compound, conflating a compounded drug with the brand

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard